Table 2.
First-line treatment and response
| Variable | No. (%) (n=15) |
|---|---|
| Treatment regimen | |
| Infusional 5-FU/Leucovorin | 4 (27) |
| Gemcitabine monotherapy | 5 (33) |
| GEM-CAP | 2 (13) |
| FOLFOX | 2 (13) |
| CCRT followed by capecitabine maintenance | 2 (13) |
| Response to the first-line treatment | |
| CRa) | 1 (7) |
| PRa) | 4 (27) |
| SD | 5 (33) |
| PD | 2 (13) |
| NAb) | 3 (20) |
5-FU, 5-fluorouracil; GEM-CAP, gemcitabine plus capecitabine; FOLFOX, oxaliplatin plus 5-FU/leucovorin; CCRT, concurrent chemoradiotherapy; CR, complete response; PR, paritial response; SD, stable disease; PD, progressive disease; NA, not applicable; sLV5FU2, simplified leucovorin and 5-FU regimen.
a)
One CR and one PR patients received CCRT with capecitabine followed by capecitabine for their locally advanced disease. The other three PR patients received sLV5FU2, GEM-CAP, and FOLFOX,
b)
Among three patients with NA for response evaluation, two patients were lost from early follow-up and one had no measurable lesion.